Popular Articles

Editorial, Opinion Piece Respond To Health Care Reform Issues
President Obama is "right to push for [health care] reform now, despite calls to postpone efforts solely on the economic recovery," a Philadelphia Inquirer editorial states. According to the editorial, cost-cutting initiatives proposed by industry groups earlier this week "may not amount to anything" because they are voluntary and "providers" past efforts at containing costs have failed every time." However, the groups" vow to reduce future health care spending by $2 trillion "shows how much fat and waste is in the system," according to the Inquirer. The editorial also states that the "most assured means of tamping down costs while providing greater access to health coverage could be through" a government-run public health insurance option. In addition, Obama "needs to warm to the idea of requiring that all Americans obtain health insurance," in order to spread out the cost of care, the editorial continues. The editorial concludes that "it"s encouraging that Obama doesn"t plan to let a couple of wars and a recession sidetrack him from his pledge to reform health care and expand coverage to all Americans" (Philadelphia Inquirer, 5/14). Opinion Piece
generic viagra
Elsevier's PharmaPendium Introduces The FDA Classic Collection
PharmaPendium, Elsevier"s online re for authoritative preclinical, clinical and post-marketing drug information, has significantly expanded its coverage of US Food and Drug Administration (FDA) approval documents with the launch of the FDA Classic Collection. This collection contains all available historical FDA approval documents up to and including those issued in 1991 - all indexed and made searchable for the first time in history. With the addition of the FDA Classic Collection, PharmaPendium has become the only integrated, searchable of all FDA drug approval documents.
Zubni implantati
News of the day
The Endocrine Society Receives Commendation From The ACCME For Excellent Continuing Medical Education Programming
The Endocrine Society received the highest level of accreditation, "Accreditation with Commendation," as a provider of continuing medical education (CME) for physicians. Awarded by the Accreditation Council for Continuing Medical Education (ACCME), the accreditation term will run through July 31, 2015.
Cardiovascular

Long-term Health And Social Outcomes For Neuroblastoma Survivors

Survivors of the childhood cancer neuroblastoma are eight times more likely to have chronic health conditions, less likely to be married, and more likely to have lower incomes than their siblings, according to a study published online July 31 in the Journal of the National Cancer Institute. This study was undertaken because minimal information exists on the long-term outcomes for neuroblastoma survivors. Caroline Laverdiere, M.D., of the Sainte-Justine Hospital in Montreal, and colleagues looked at data for 954 5-year neuroblastoma survivors who were diagnosed from 1970-1986 and enrolled in the Childhood Cancer Survivor Study (CCSS). Late mortality, second malignant tumors, and chronic health conditions were analyzed. The researchers also compared participants with a cohort of 3,899 siblings of children with cancer for risk of chronic health conditions and sociodemographic outcomes. Neuroblastoma survivors were less likely to be married or employed with high income than the controls from the sibling cohort, and after 20 years follow-up, were more than eight times more likely to have chronic health conditions, such as neurological, endocrine, sensory, and musculoskeletal complications. "ò€¦Results of the current study are quite relevant and underscore the need for close surveillance and life-long follow-up to ameliorate potential medical and psychosocial late effects," the authors write. "Future research should build on these data and investigate risk factors for long-term complications of neuroblastoma treatment and second malignant neoplasmsò€¦" In an accompanying editorial, Elizabeth Fox, M.D., of the Pediatric Oncology Branch at the Center for Cancer Research, National Cancer Institute, in Bethesda, Md., Deborah Citron, M.D., of the Radiation Oncology Branch at NCI, and Frank M. Balis, M.D, of the Children"s Hospital of Philadelphia, point out that survivors who were treated with multimodal therapy in this time frame had twice as much risk of late effects as survivors who had localized neuroblastomas that could be treated with surgery alone. Because surviving neuroblastoma patients from the 1970s were less likely than both current neuroblastoma patients and survivors of other childhood cancers from the 1970s to have been treated with intensive therapies, this population probably has fewer late-arising complications than might be expected for either of the latter two groups. "The introduction of more selective and less toxic molecularly-targeted drugs holds the promise of substantially altering the acute and long-term toxic effects of cancer therapy," the editorialists write. "The potential requirement for extended treatment with these drugs may have a substantial impact on a child"s development and will require careful study of late effects, similar to the ongoing efforts of the CCSS." Links: Article Editorial Journal of the National Cancer Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):